ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CEO Jacob Chacko Sells 2,801 Shares of Stock

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CEO Jacob Chacko sold 2,801 shares of the business’s stock in a transaction that occurred on Monday, September 13th. The stock was sold at an average price of $25.02, for a total transaction of $70,081.02. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Jacob Chacko also recently made the following trade(s):

  • On Friday, September 10th, Jacob Chacko sold 2,942 shares of ORIC Pharmaceuticals stock. The stock was sold at an average price of $25.08, for a total transaction of $73,785.36.
  • On Tuesday, September 7th, Jacob Chacko sold 5,981 shares of ORIC Pharmaceuticals stock. The shares were sold at an average price of $25.11, for a total value of $150,182.91.

NASDAQ ORIC opened at $24.96 on Wednesday. The firm has a 50-day simple moving average of $19.53 and a 200 day simple moving average of $22.26. ORIC Pharmaceuticals, Inc. has a twelve month low of $15.67 and a twelve month high of $40.81. The stock has a market cap of $981.38 million, a PE ratio of -9.24 and a beta of 2.91.

ORIC Pharmaceuticals (NASDAQ:ORIC) last issued its quarterly earnings results on Tuesday, August 10th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.08). On average, sell-side analysts predict that ORIC Pharmaceuticals, Inc. will post -2.24 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the company. O Shaughnessy Asset Management LLC acquired a new position in ORIC Pharmaceuticals in the second quarter valued at about $27,000. Cubist Systematic Strategies LLC acquired a new position in ORIC Pharmaceuticals in the first quarter valued at about $33,000. Great West Life Assurance Co. Can lifted its stake in ORIC Pharmaceuticals by 133.8% in the first quarter. Great West Life Assurance Co. Can now owns 1,440 shares of the company’s stock valued at $35,000 after buying an additional 824 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in ORIC Pharmaceuticals in the first quarter valued at about $40,000. Finally, Royal Bank of Canada lifted its stake in ORIC Pharmaceuticals by 291.2% in the first quarter. Royal Bank of Canada now owns 1,991 shares of the company’s stock valued at $49,000 after buying an additional 1,482 shares during the period. 91.96% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms have commented on ORIC. upgraded ORIC Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $34.00 price target on the stock in a research note on Tuesday, July 6th. upgraded ORIC Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $34.00 price target for the company in a research note on Tuesday, July 6th. HC Wainwright cut their price objective on ORIC Pharmaceuticals from $54.00 to $53.00 and set a “buy” rating for the company in a research report on Wednesday, August 11th. Zacks Investment Research cut ORIC Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, Robert W. Baird reaffirmed a “buy” rating and set a $45.00 price objective on shares of ORIC Pharmaceuticals in a research note on Sunday, June 6th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to data from MarketBeat, ORIC Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $37.00.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors.

Featured Story: What strategies should day traders use to execute a trade?

Insider Buying and Selling by Quarter for ORIC Pharmaceuticals (NASDAQ:ORIC)

Receive News & Ratings for ORIC Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORIC Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.